BSE SENSEX S&P CNX 26,838 8,112 Bloomberg DRRD IN Equity Shares (m) 170.4 M.Cap. (INR b)/(usd b) 718/11.2 52-Week Range (INR) 4838/2996 1, 6, 12 Rel. Per (%) -4/28/39 Avg Val, INR m 1341 Free float (%) 74.5 Financials & Valuation (INR b) Y/E MAR 2015 2016E 2017E Sales 148.2 167.7 195.1 EBITDA 33.5 46.3 49.9 Net Profit 22.2 31.1 33.1 EPS (INR) 130.2 182.3 194.2 EPS Gr. (%) 4.5 40.1 6.5 BV/Sh. (INR) 653.2 812.1 974.3 RoE (%) 19.9 22.4 19.9 RoCE (%) 16.9 21.9 20.0 P/E (x) 32.4 23.1 21.7 P/BV (x) 6.5 5.2 4.3 Estimate change TP change Rating change 29 October 2015 2QFY16 Results Update Sector: Healthcare Dr Reddy s Labs CMP: INR4,214 TP: INR4,915 (+17%) Buy Results ahead of estimates; margin improvement surprising Dr Reddy s (DRRD) 2QFY16 PAT at INR7.2b (+26% YoY) was 22% ahead of estimates, driven by 590bp margin improvement in 2Q. The margin improvement was surprising as DRRD has not launched any significant product during the last six months. Revenue was in line at INR39.9b (up 11.2% YoY) on the back of resilient US sales in 2Q. US, India and EU lead in segments: US business posted 29.9% YoY growth (5% beat) on the back of sustained market share in key injectable and scale-up in Habitrol sales. India sales grew 14% YoY to INR5.5b, in line with our estimate. Europe business reported 48% YoY growth on the back of two big product launches. However, RoW business declined 24% YoY in 2Q, with Venezuela witnessing lower sales. Russia/CIS declined 18%YoY on the back of sharp currency depreciation. Highest EBITDA margin till date: 2Q EBITDA margin at 28.6% was 529bp ahead of expectation (23.3%) as gross margin improved 234bp YoY and SG&A expenses declined 1.5% YoY due to ongoing cost rationalization activities. Gross margin for global generics was 67.3% and 25.8% for the PSAI segment. Going ahead, we expect margin to normalize at 25-27% due to niche US launches (gnexium, ggleevec, gcopaxone and complex injectables) and improved operating leverage. Earnings call takeaways: (1) Improvement in SG&A is likely to be sustainable. (2) In Oct 15, customers sourcing APIs from Srikakulam plant have received rescission letter for two ANDAs. (3) No clarity on audit timeline from US FDA for Srikakulam plant. (4) To launch Gleevec after SUNP s exclusivity period is over. (5) Russia business to see revival in 2HFY16. (6) Copaxone launch likely to be delayed due to ongoing query. Valuation and view: We project 21% CAGR growth in EPS over FY15-18 driven by (1) low-competition product launches in the US, (2) improved India business, (3) stabilized Russian currency and (4) improved profitability (400bp over FY15-18). Valuation discount to large peers (12-15%) would narrow on improving growth visibility (niche US pipeline). We reiterate Buy rating on the stock with a TP of INR4,915 (23x Sep 17E P/E 12-15% discount to large peers). Key risks: Escalation of regulatory issues (API plant) and delay in US approvals. Amey Chalke (Amey.Chalke@MotilalOswal.com); +91 22 3982 5423 Investors are advised to refer through disclosures made at the end of the Research Report. Motilal Oswal research is available on www.motilaloswal.com/institutional-equities, Bloomberg, Thomson Reuters, Factset and S&P Capital.
Result snapshot Exhibit 1: Quarterly Snapshot (Revenue mix) (INR m) 2QFY15 1QFY16 2QFY16 YoY QoQ FY15 FY16E YoY Global Generics 28869 30961 32768 13.5 5.8 120,556 138,211 14.6 North America 14293 18515 18563 29.9 0.3 64,723 79,611 23.0 Europe 1434 1912 2124 48.1 11.1 7,193 8,739 21.5 India 4799 4756 5464 13.9 14.9 17,870 21,444 20.0 Russia/CIS 4798 3078 3917 (18.4) 27.3 17,713 15,291 (13.7) RoW 3545 2700 2700 (23.8) 0.0 13,057 13,126 0.5 PSAI 6392 5614 5918 (7.4) 5.4 25,456 25,135 (1.3) North America 1298 664 692 (46.7) 4.2 4,605 4,380 (4.9) Europe 1493 2352 2426 62.5 3.1 10,507 10,023 (4.6) India 2020 587 724 (64.2) 23.3 3,288 2,959 (10.0) Others 1581 2011 2076 31.3 3.2 7,056 7,773 10.2 Proprietary products 618 1003 1204 94.8 20.0 2,177 4,354 100.0 Total revenues 35879 37578 39890 11.2 6.2 148,189 167,700 13.2 Exhibit 2: Quarterly Profit and Loss statement (INR m) 2QFY15 1QFY16 2QFY16 YoY QoQ FY15 FY16E YoY Total revenues 35879 37578 39890 11.2 6.2 148,189 167,700 13.2 Cost of revenues 14893 14631 15421 3.5 5.4 62,786 64,565 2.8 Gross profit 20986 22947 24469 16.6 6.6 85,403 103,136 20.8 Gross margin (%) 58.5 61.1 61.3 285 bp 28 bp 57.6 61.5 387 bp SG&A expenses 8716 8705 8592 (1.4) (1.3) 34,482 37,733 9.4 % of Total Revenues 24.3 23.2 21.5 (275)bp (163)bp 23.3 22.5 (77)bp R&D Expenditure 4113 4387 4473 8.8 2.0 17,449 19,118 9.6 % of Total Revenues 11.5 11.7 11.2 (25)bp (46)bp 11.8 11.4 (37)bp EBITDA 8157 9855 11404 39.8 15.7 33,472 46,285 38.3 EBITDA margin (%) 22.7 26.2 28.6 585 bp 236 bp 22.6 27.6 501 bp Amortization expenses 1957 2268 2466 26.0 8.7 8,103 9,224 13.8 % of Total Revenues 5.5 6.0 6.2 73 bp 15 bp 5.5 5.5 3 bp Other operating income (265) (125) (320) 20.7 156.1 (917) (1,900) 107.3 Operating profit 6465 7712 9258 43.2 20.0 26,286 38,962 48.2 OPM (%) 18.0 20.5 23.2 519 bp 269 bp 17.7 23.2 549 bp Forex loss/(gain) 118 (12) 349 na (3,008.3) (1,759) 0 (100.0) Finance expenses (539) (204) (133) na (35.0) 77 362 368.4 Equity in loss of affiliates (51) (49) (56) 10.4 14.4 (195) (230) 18.1 PBT 6937 7977 9098 31.1 14.1 28,163 38,830 37.9 Income tax 1196 1721 1879 57.1 9.2 5,984 7,766 29.8 Effective tax rate (%) 17.2 21.6 20.7 341 bp (92)bp 21.2 20.0 (125)bp Net income - reported 5741 6256 7219 25.7 15.4 22,179 31,064 40.1 Exceptionals 0 0 0 na na 629 0 Adjusted Net Profit 5741 6256 7219 25.7 15.4 22,179 31,064 40.1 29 October 2015 2
Business highlights 2Q Revenues grew 11% YoY to INR 39.9b (USD 609m, flat YoY), primarily driven by sustained traction in US business. Global Generics business growth was in line at 13.5% YoY, led by strong growth in US, India, and Europe business. PSAI business declined 7%YoY to INR5.9b (8% miss) and Innovator product segment posted 95%YoY growth (65% beat) in 2Q. North America (47% of sales): In 2Q, on constant currency basis, DRRD grew 4% YoY (1% QoQ) to USD 286m, aided by Habitrol launch (OTC brand) and sustained market share in key injectable products. DRRD has also settled for generic Gleevec and expected to launch this product after SUNP s exclusivity. However, copaxone 20mg approval could be delayed due to pending query that could take at least two quarters for DRRD to successfully reply to US FDA. Exhibit 3: Resilient US biz grew 14%YoY (in dollar terms) US sales (USD m) One-off sales (USD m) Exhibit 4: ANDA filings - quarterly trend ANDA approval ANDA filed 9 213 262 242 275 236 271 279 292 286 3 2 5 4 2 2 3 5 2 4 2 2 1 1 0 6 1 2 2Q FY14 2Q FY16 1Q FY14 2Q FY14 2QFY16 In 2Q, company had filed for two new products in the US, taking cumulative ANDA filings to 227. Pending ANDAs stands at 76 including 50 Para IVs of which 18 are FTFs. India (13% of sales): India business delivered double digit growth for 7 th consecutive quarter, on account of sustained improvement in the performance of the top brands. The company has successfully integrated UCB brands in 2Q. According to AIOCD, Dr Reddys growth in domestic market was at 13.6% (secondary market data) for the Jul-Sep 15 quarter, much ahead of industry growth of 12%. 29 October 2015 3
Exhibit 5: India formulation sales improving India form. (INR m) YoY growth (%) 17.8 14.5 10.6 15.7 8.5 14.1 5.2 4744 4207 3913 4101 3999 4799 4328 18.9 13.9 4756 5464 2Q FY14 2Q FY16 RoW sales including Russia/CIS (7% of sales): Sharp depreciation in Russian ruble as well as ongoing macro-economic issues (in CIS region) led to 29% YoY decline in Russia/CIS sales. (Constant currency growth 11% YoY). Increase in drug prices from the DRRD and retailers led to significant volume decline for DRRD in 1Q. However, these price hikes have been taken back, resulting in healthy constant currency growth going ahead. The company has also guided for better traction in Russia business for next few quarters. Exhibit 6: Russian sales impacted by Rouble weakness Russia form. (INR m) Exhibit 7: Constant currency growth in Russia return to 11% Constant currency growth (%) Absolute growth (%) 4616 4300 3754 4200 4130 3960 2630 2278 2917 30 43 17 7 5 18 4 15 27-11 -8 0 17-30 -46-20 11-29 2Q FY14 2Q FY16 2Q FY14 2Q FY16 Venezuela sales contribution weakens in 2Q: Venezuela sales declined in 2Q, for 2 nd consecutive quarter. The company has been remitting funds from its Venezuelan subsidiary at official exchange rate of 6.3 bolivar/usd (CENCOEX rate). However, certain monetary assets and liabilities may not qualify for this rate have been translated at the rate of VED 198.5 per USD, resulting in INR 39m loss in 2Q. Current receivables from Venezuela market stand at USD 60m v/s USD 50m in 1Q). Going ahead, The Company would calibrate its growth in this market, depending on its ability to get funds repatriated. Europe (5% of sales): DRRD registered 48%YoY growth in Europe sales at INR2.1b, driven by two product launches in 1Q (Aripiprazole and Pregabalin). The company is expected to launch few more products in coming quarters. Margins at historical high: 2Q EBITDA margins at 28.6% were 529bp ahead of expectations (23.3%) as gross margins improved 234bp YoY and SG&A expenses declined 1.4% YoY due to ongoing cost controlled efforts across the segments 29 October 2015 4
going on since last quarter. We expect margin to normalize going ahead at 25-27% led by niche US launches (gnexium, complex injectables) & operating leverage. Exhibit 8: Gross Margin (%) Gross profit (INR b) Gross margin (%) 60.5 61.1 61.3 59.3 58.0 58.5 58.2 57.2 54.8 Exhibit 9: EBITDA Margin (%) EBITDA (INR b) EBITDA margin (%) 29.0 25.2 26.2 21.8 23.2 22.7 23.2 21.3 28.6 19 21 20 21 21 22 21 23 24 8 10 8 8 8 9 8 10 11 2Q FY14 2Q FY16 2Q FY14 2Q FY16 Better product mix drives gross margins: Overall gross margins at 61.3% (Up 285bp YoY) were driven by better business/product mix and cost control activities at plant level. Gross margins for Global generics and PSAI segment stood at 67.3% and 25.8%, respectively. PSAI gross margins improvement was led by product mix in 2Q. Exhibit 10: Gross margin quarterly trend (Segment wise) Global generics (%) PSAI (%) 66 68 66 67 66 66 63 68 67 25 16 16 22 27 17 23 24 26 Sep-13 Dec-13 Mar-14 Jun-14 Sep-14 Dec-14 Mar-15 Jun-15 Sep-15 R&D spends remain high: R&D expense was at 11.2% of sales at INR 4.5b v/s 11.5% of sales in 2QFY15. Scale in R&D is according to plan and expected to remain at higher level due to strong product pipeline of complex generics, Biosimilars and Proprietary products. DRRD spends 12-15% of their total R&D on Biosimilar research. 29 October 2015 5
Exhibit 11: R&D expense on increasing trend R&D cost (INR b) R&D / sales (%) 13.3 11.4 11.0 11.5 11.2 9.0 8.4 11.7 11.2 3.0 3.0 4.0 3.9 4.1 4.3 5.1 4.4 4.5 2Q FY14 2Q FY16 Derivative hedges stand at USD300m at INR61-65.4/USD, while balance sheet hedges are at USD135m (at average rate of INR60-65/USD). Cash flow hedges in other currencies stood at RUB960m at INR1.16/RUB and EURO6m at 73.7/EUR (maturing over next 6 months). Srikakulam facility: In Oct 15, DRRD s customers, who were sourcing their APIs from Srikakulam facility, have received Rescission letter from the US FDA for non-compliance of CGMP practices. It has also highlighted that this facility has received severe 483 observations under OAI category during last inspection (in Dec 14). Since the inspection DRRD has not received any approval from this facility. The management clarified that they have completed all remedial measures for this facility and expects one more US FDA inspection in the near future. It could take few more months to get the clearance from the US FDA. Meanwhile site transfer process for key products is still on. The company has also launched one of the site transferred product Nexium in 2Q. 29 October 2015 6
Operating metrics Exhibit 12: Key operating metrics 3QFY13 4QFY13 1QFY14 2QFY14 3QFY14 4QFY14 1QFY15 2QFY15 3QFY15 4QFY15 1QFY16 2QFY16 Revenue Mix (%) USA 32.3 34.2 38.2 39.4 45.9 43.0 46.8 39.8 43.8 44.3 49.3 46.5 India 13.0 10.4 12.3 12.5 11.1 11.8 11.4 13.4 11.3 12.3 12.7 13.7 Europe 6.7 5.5 5.5 5.2 5.3 5.1 4.1 4.0 5.1 6.0 5.1 5.3 LatAm 15.3 13.5 15.8 16.4 15.0 13.0 13.8 13.4 12.4 8.5 8.2 9.8 RoW 5.4 4.0 5.2 5.4 5.9 5.6 6.3 9.9 10.0 9.0 7.2 6.8 CRAMs 24.9 30.5 20.6 19.1 14.3 19.1 15.7 17.8 15.9 19.2 14.9 14.8 Innovative products 2.4 2.0 2.4 1.9 2.5 2.4 1.8 1.7 1.6 0.8 2.7 3.0 Revenue Gr. (%) 3.5 25.6 12.0 16.5 23.3 4.2 23.6 6.9 8.7 11.2 6.8 11.2 USA (16.8) 30.7 37.3 42.9 75.5 31.1 51.5 7.9 3.7 14.6 12.4 29.9 India 11.6 8.7 0.3 8.5 5.2 17.8 14.5 14.1 10.6 15.7 18.9 13.9 Europe (20.4) 1.7 (27.8) (0.9) (3.6) (3.1) (7.2) (18.6) 4.6 32.0 31.0 48.1 LatAm 32.0 27.5 7.7 43.6 20.9 (0.0) 8.3 (13.0) (10.0) (27.2) (36.7) (18.4) RoW 41.8 18.4 12.0 36.2 35.1 48.3 50.0 94.8 82.3 76.8 21.9 (23.8) CRAMs 28.1 35.9 6.2 (18.7) (29.0) (34.7) (5.6) (0.2) 20.7 11.7 1.4 (7.4) Innovative products (17.3) (5.7) (16.5) (24.8) 26.4 28.5 (6.6) (1.0) (28.9) (65.2) 58.2 94.8 As % of sales Raw material 44.6 46.4 43.3 42.0 39.5 42.8 40.7 41.5 41.8 45.2 38.9 38.7 SG&A 28.5 24.8 29.2 23.8 23.1 24.0 25.0 24.3 23.7 20.3 23.2 21.5 R&D cost 7.1 7.3 8.5 9.0 8.4 11.4 11.0 11.5 11.2 13.3 11.7 11.2 Tax Rate 18.5 27.3 12.8 10.3 29.0 20.6 21.5 17.2 30.7 20.0 21.6 20.0 Margins (%) Gross Margins 55.4 53.6 56.7 58.0 60.5 57.2 59.3 58.5 58.2 54.8 61.1 61.3 EBITDA Margins 19.8 21.5 19.0 25.2 29.0 21.8 23.2 22.7 23.2 21.3 26.2 28.6 EBIT Margins 15.0 17.0 13.3 20.0 24.0 16.2 17.9 17.3 17.9 15.5 20.2 22.4 PAT margins 10.8 13.7 12.7 20.6 16.1 13.8 15.6 16.0 16.3 13.7 16.6 18.1 Source: Company; MOSL 29 October 2015 7
Valuation and view Successful monetization of several niche products (gvalcyte, gdacogen) has helped DRRD achieve a formidable base in the US. With fewer new launches in the US and concerns on Russian market, FY16 would be a year of consolidation for DRRD. However, we expect upside from US portfolio and healthy domestic growth to result in 22% EPS CAGR over FY15-18E to be driven by 15% revenue growth and cumulative 400bp operating margin expansion. Our TP of INR 4,915 implies 17% upside from current levels. We value DRRD at 23x Sep 17E EPS, at 10% premium to sector average (one-year forward P/E) and at 12-15% discount to large peers due to: With stronger earnings growth of 22% CAGR (23% for larger peers) Healthy Balance Sheet (D/E: 0.3x) and return ratios (RoE at 20%) Strong product pipeline (18 FTFs, proprietary products and Biosimilars ) Key catalysts to drive stock s performance over the medium term are: Stabilisation of emerging market economies/currency, mainly Russia/CIS (12% of sales). Clearance of Form 483 issues at Srikakulam API facility Launch of key products like gcopaxone, ggleevec, etc Key risks to our investment thesis: Regulatory delays affecting key US launches, Adverse outcome of pending FDA issues (API facility) Further depreciation of Russian currency. Every 10% depreciation of Ruble hereon (vs USD) leads to 2% downgrade in EPS estimate (annualized). 29 October 2015 8
Story in charts Exhibit 13: Formulation led sales growth (INR b) Formulations (INR b) API (INR b) 29 27 25 25 24 31 24 20 20 49 53 70 83 105 121 138 163 190 Exhibit 15: US Sales to grow at 19-20% CAGR over FY15-18E Core US sales (INR b) YoY Growth (%) Exhibit 14: India formulation business DF Revenue (INR b) YoY Growth (%) 19.8 20.0 15.1 16.0 16.0 13.7 12.6 10.6 7.9 10 12 13 15 16 18 21 25 29 Exhibit 16: PSAI business to see moderate growth ahead PSAI Sales (INR b) YoY Growth (%) 14 15 77 56 32 27 35 55 65 80 94 111 11 7 18 23 19 18 21 29 9 24 6 8 7-4 -1-22 20 20 24 31 25 25 27 29 FY10 FY11 FY12 FY13 FY14E FY15 FY16E FY17E FY18E Exhibit 17: EBITDA margins improving with product mix Gross Margin (%) EBITDA Margin (%) 55.5 57.9 58.9 55.4 58.2 57.6 61.5 59.4 60.0 20.2 21.0 24.5 21.3 24.0 22.6 27.6 25.6 26.5 Exhibit 18: EBITDA growth to improve in FY16-17E EBITDA (INR b) Growth (%) 52 38 28 20 10 4 6 8-6 14 16 24 25 32 33 46 50 60 29 October 2015 9
Exhibit 19: Strong earnings growth expected ahead Core EPS (INR/ share) 0 0 0 Exhibit 20: Rich ANDA pipeline ANDA filed ANDA pending 209 220 227 187 193 158 170 138 66 73 81 125 130 182 194 233 FY11 FY12 FY13 FY14 FY15 FY16E FY17E FY18E 68 73 75 80 65 62 73 76 FY09 FY10 FY11 FY12 FY13 FY14 FY15 YTD Exhibit 21: R&D expense higher due to NCE research Exhibit 22: OTC share growing in Russia sales R&D expense (INR b) % of sales Rx (USD m) OTC (USD m) OTC ( % of sales ) 5.4 6.8 6.1 6.7 9.4 11.8 11.4 11.5 11.5 27 18 51 26 67 29 88 105 39 34 36 88 4 5 6 8 12 17 19 22 26 125 145 165 170 165 157 FY10 FY11 FY12 FY13 FY14 FY15 Exhibit 23: Return ratios lower with lower margins Exhibit 24: Fixed asset turnover (x) 24.1 16.8 21.6 19.7 RoE (%) RoCE (%) 23.3 22.4 18.7 19.9 21.9 17.2 18.7 16.9 19.9 19.9 20.0 21.1 2.4 Gross block (INR b) Fixed Asset turnover 2.2 2.2 2.1 2.1 2.1 2.0 1.9 2.0 3.1 2.5 30 38 44 53 63 72 85 96 107 29 October 2015 10
Financials and valuations Key assumptions Segment growth (%) 2011 2012 2013 2014 2015 2016E 2017E 2018E USA (15.2) 13.0 67.9 18.7 46.1 17.0 23.0 18.6 India 19.8 15.1 10.6 12.6 7.9 13.7 20.0 16.0 Europe (18.9) (12.6) (2.0) (6.6) (9.7) 3.2 21.5 15.6 Russia 19.6 19.1 22.1 27.5 17.2 (10.6) (13.7) 17.2 Others 46.4 17.3 16.0 41.7 33.0 77.4 0.5 15.6 PSAI 8.8 (3.7) 21.2 28.9 (21.9) 6.2 (1.3) 7.8 Innovative products 41.9 34.6 57.3 11.9 1.1 (28.2) 100.0 25.0 Total Sales 1.2 6.3 29.5 20.2 13.7 12.1 13.2 16.3 Expenses Cost of sales (%) 44.5 42.1 41.1 44.6 41.8 42.4 38.5 40.6 EBITDA Margin (%) 20.2 21.0 24.5 21.3 24.0 22.6 27.6 25.6 Income Statement (INR Million) Y/E March 2011 2012 2013 2014 2015 2016E 2017E 2018E Net Sales 74,693 96,738 116,266 132,171 148,189 167,700 195,066 226,190 Change (%) 6.3 29.5 20.2 13.7 12.1 13.2 16.3 16.0 Other Income 1,118 1,669 3,634 2,411 2,871 2,130 2,510 2,510 Total Expenditure 15,660 23,742 24,763 31,699 33,472 46,285 49,937 59,940 EBITDA 10.3 51.6 4.3 28.0 5.6 38.3 7.9 20.0 Change (%) 21.0 24.5 21.3 24.0 22.6 27.6 25.6 26.5 Margin (%) 4,147 6,254 6,237 7,085 8,103 9,224 10,729 12,440 Depreciation & Amort. 11,513 17,488 18,526 24,614 25,369 37,062 39,208 47,500 EBIT 0 0 0 0 0 0 0 0 Net Interest Exp 189 118 79 77 362 362 337 Forex (Gains)/Losses 0 0 365 329 0 0 0 0 PBT after EO Expense 12,442 19,157 21,677 26,616 28,163 38,830 41,357 49,673 Tax 506.0 54.0 13.2 22.8 5.8 37.9 6.5 20.1 Tax Rate (%) 12,442 19,157 21,677 26,616 28,163 38,830 41,357 49,673 Reported PAT 1,403 4,204 4,900 5,093 5,984 7,766 8,271 9,935 Adjusted Net Profit 11.3 21.9 22.6 19.1 21.2 20.0 20.0 20.0 Change (%) 11,099 12,428 13,682 21,188 22,179 31,064 33,085 39,739 Margin (%) 939.2 12.0 10.1 54.9 4.7 40.1 6.5 20.1 Balance Sheet (INR Million) Y/E March 2011 2012 2013 2014 2015 2016E 2017E 2018E Equity Share Capital 846 848 849 851 852 852 852 852 Reserves 45,144 56,596 72,256 89,950 110,450 137,534 165,168 199,100 Net Worth 45,990 57,444 73,105 90,801 111,302 138,386 166,020 199,952 Loans 23,503 32,210 36,678 44,742 43,126 36,164 36,164 31,164 Deferred Liabilities/Tax 87-833 -1,669-3,310-4,013-4,013-4,013-4,013 Capital Employed 69,580 88,821 108,114 132,233 150,414 170,538 198,171 227,103 Gross Block 38,359 44,064 52,958 63,444 72,011 85,071 96,130 107,190 Less: Accum. Deprn. 14,714 18,086 21,213 25,695 30,040 35,543 41,602 48,161 Net Fixed Assets 29,642 33,246 37,814 44,424 48,090 55,646 60,647 65,148 Investments 622 11,558 18,131 26,384 38,871 30,262 30,262 30,262 Goodwill/Intangibles 15,246 13,529 14,021 14,697 16,430 16,227 16,227 16,228 Curr. Assets 47,560 59,179 68,751 78,664 85,580 102,830 132,647 162,775 Inventory 16,059 19,352 21,600 23,992 25,529 30,023 36,826 42,071 Account Receivables 17,615 25,339 31,972 33,037 40,755 41,301 48,040 55,706 Cash and Bank Balance 5,729 7,379 5,136 8,451 5,394 14,737 28,273 40,117 Others 8,157 7,109 10,043 13,184 13,901 16,770 19,507 24,881 Curr. Liability & Prov. 23,490 28,691 30,603 31,936 38,556 34,429 41,612 47,310 Account Payables 8,480 9,502 11,862 10,503 10,660 12,336 15,132 17,287 Other Current Liabilities 15,010 19,189 18,741 21,433 27,896 22,092 26,480 30,023 Net Current Assets 24,070 30,488 38,148 46,728 47,024 68,402 91,034 115,465 Appl. of Funds 69,580 88,821 108,114 132,233 150,415 170,538 198,171 227,103 E: MOSL Estimates 29 October 2015 11
Financials and valuations Ratios 0.56302 0.5375 Y/E March 2011 2012 2013 2014 2015 2016E 2017E 2018E Basic (INR) EPS 65.6 73.3 80.6 124.6 130.2 182.3 194.2 233.2 Cash EPS 90.1 110.2 117.3 166.2 177.7 236.4 257.1 306.2 BV/Share 271.8 338.7 430.5 533.8 653.2 812.1 974.3 1,173.4 DPS 11.2 13.7 13.8 18.0 20.0 27.3 29.1 35.0 Payout (%) 20.2 18.2 16.3 16.6 17.9 17.6 17.6 17.6 Valuation (x) P/E 57.5 52.3 33.8 32.4 23.1 21.7 18.1 Cash P/E 0.0 4.8 5.2 0.6 6.9 0.6 3.3 0.9 P/BV 12.4 9.8 7.9 6.5 5.2 4.3 3.6 EV/Sales 7.6 6.3 5.5 4.8 4.2 3.6 3.0 EV/EBITDA 30.8 29.5 23.0 21.4 15.3 13.9 11.3 Dividend Yield (%) 0.3 0.3 0.4 0.5 0.6 0.7 0.8 Return Ratios (%) RoE 24.1 21.6 18.7 23.3 19.9 22.4 19.9 19.9 RoCE 16.8 19.7 17.2 18.7 16.9 21.9 20.0 21.1 Working Capital Ratios Fixed Asset Turnover (x) 2.2 2.3 2.4 2.3 2.2 2.1 2.2 2.2 Debtor (Days) 86 96 100 91 100 90 90 90 Inventory (Days) 78 73 68 66 63 65 69 68 Working Capital (Days) 90 87 104 106 103 117 117 122 Leverage Ratio Current Ratio (x) 2.0 2.1 2.2 2.5 2.2 3.0 3.2 3.4 Debt/Equity (x) 0.5 0.6 0.5 0.5 0.4 0.3 0.2 0.2 Cash Flow Statement (INR Million) Y/E March 2011 2012 2013 2014 2015 2016E 2017E 2018E Op. Profit/(Loss) before Tax 15,660 23,742 24,763 31,699 33,472 46,285 49,937 59,940 Interest/Dividends Recd. 929 1,669 3,151 2,003 2,793 1,768 2,148 2,173 Direct Taxes Paid -1,403-4,204-4,900-5,093-5,984-7,766-8,271-9,935 (Inc)/Dec in WC -6,501-4,768-9,903-5,265-3,353-12,035-9,096-12,586 CF from Operations 8,685 16,439 13,111 23,344 26,929 28,252 34,718 39,593 (inc)/dec in FA -12,603-8,141-11,297-14,371-13,502-16,577-15,729-16,942 Free Cash Flow -3,918 8,298 1,814 8,973 13,427 11,675 18,988 22,651 (Pur)/Sale of Investments 3,531-10,936-6,573-8,253-12,487 8,609 0 0 CF from Investments -9,072-19,077-17,870-22,624-25,989-7,968-15,729-16,942 Change in net worth -5,740-780 1,620-247 2,302 1,472 355 1,168 (Inc)/Dec in Debt 8,847 8,707 4,468 8,064-1,617-6,962 0-5,000 Other Items -1,351-920 -836-1,640-704 0 0 0 Dividend Paid -2,224-2,719-2,736-3,581-3,979-5,452-5,806-6,974 CF from Fin. Activity -468 4,288 2,516 2,596-3,998-10,941-5,452-10,806 Inc/Dec of Cash -855 1,650-2,243 3,315-3,058 9,343 13,536 11,844 Add: Beginning Balance 6,584 5,729 7,379 5,136 8,451 5,394 14,737 28,273 Closing Balance 5,729 7,379 5,136 8,451 5,393 14,738 28,273 40,117 29 October 2015 12
Corporate profile: Dr. Reddy's Laboratories Company description Dr. Reddy's is a vertically integrated company, with presence across the pharmaceutical value chain through its core businesses of Global Generics, Pharmaceutical Services and Active Ingredients (PSAI) and Proprietary Products. Company is currently developing bio-generics and NCEs. Key focus markets include India, the US, Europe and Russia. Exhibit 34: Sensex rebased 4,500 4,000 3,500 3,000 Dr Reddy's Labs Sensex - Rebased 2,500 Oct-14 Jan-15 Apr-15 Jul-15 Oct-15 Exhibit 25: Shareholding pattern (%) Jun-15 Mar-15 Jun-14 Promoter 25.5 25.5 25.5 DII 5.9 5.4 5.4 FII 54.8 55.8 53.8 Others 13.8 13.3 15.3 Note: FII Includes depository receipts Exhibit 26: Top holders Holder Name % Holding First State Investments Management(Uk) Limited, 7.9 Oppenheimer Developing Markets Fund 4.3 Blackrock Institutional Trust Company & Their 2.9 Abu Dhabi Investment Authority 1.9 Franklin Templeton Investment Funds 1.6 Exhibit 27: Top management Name Designation Satish Reddy Chairman G V Prasad Vice Chairman & MD & CEO Exhibit 28: Directors Name Satish Reddy G V Prasad J P Moreau* Anupam Puri* Omkar Goswami* Name Sridar Iyengar* Bruce L A Carter* Kalpana Morparia* Ravi Bhoothalingam* Ashok Sekhar Ganguly* *Independent Exhibit 29: Auditors Name BSR & Co LLP Sagar & Associates Type Statutory Cost Auditor Exhibit 30: MOSL forecast v/s consensus MOSL Consensus EPS (INR) forecast forecast Variation (%) FY16 182.3 156.6 16.4 FY17 194.2 185.6 4.7 FY18 233.2 219.0 6.5 29 October 2015 13
Disclosures This document has been prepared by Motilal Oswal Securities Limited (hereinafter referred to as Most) to provide information about the company(ies) and/sector(s), if any, covered in the report and may be distributed by it and/or its affiliated company(ies). This report is for personal information of the selected recipient/s and does not construe to be any investment, legal or taxation advice to you. This research report does not constitute an offer, invitation or inducement to invest in securities or other investments and Motilal Oswal Securities Limited (hereinafter referred as MOSt) is not soliciting any action based upon it. This report is not for public distribution Dr Reddy and has been s Labs furnished to you solely for your general information and should not be reproduced or redistributed to any other person in any form. This report does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, investors should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. MOSt and its affiliates are a full-service, integrated investment banking, investment management, brokerage and financing group. We and our affiliates have investment banking and other business relationships with a some companies covered by our Research Department. Our research professionals may provide input into our investment banking and other business selection processes. Investors should assume that MOSt and/or its affiliates are seeking or will seek investment banking or other business from the company or companies that are the subject of this material and that the research professionals who were involved in preparing this material may educate investors on investments in such business. The research professionals responsible for the preparation of this document may interact with trading desk personnel, sales personnel and other parties for the purpose of gathering, applying and interpreting information. Our research professionals are paid on the profitability of MOSt which may include earnings from investment banking and other business. MOSt generally prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, MOSt generally prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover. Our salespeople, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing among other things, may give rise to real or potential conflicts of interest. MOSt and its affiliated company(ies), their directors and employees and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the affiliates of MOSt even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report Reports based on technical and derivative analysis center on studying charts company's price movement, outstanding positions and trading volume, as opposed to focusing on a company's fundamentals and, as such, may not match with a report on a company's fundamental analysis. In addition MOST has different business segments / Divisions with independent research separated by Chinese walls catering to different set of customers having various objectives, risk profiles, investment horizon, etc, and therefore may at times have different contrary views on stocks sectors and markets. Unauthorized disclosure, use, dissemination or copying (either whole or partial) of this information, is prohibited. The person accessing this information specifically agrees to exempt MOSt or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOSt or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOSt or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays. The information contained herein is based on publicly available data or other sources believed to be reliable. Any statements contained in this report attributed to a third party represent MOSt s interpretation of the data, information and/or opinions provided by that third party either publicly or through a subscription service, and such use and interpretation have not been reviewed by the third party. This Report is not intended to be a complete statement or summary of the securities, markets or developments referred to in the document. While we would endeavor to update the information herein on reasonable basis, MOSt and/or its affiliates are under no obligation to update the information. Also there may be regulatory, compliance, or other reasons that may prevent MOSt and/or its affiliates from doing so. MOSt or any of its affiliates or employees shall not be in any way responsible and liable for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. MOSt or any of its affiliates or employees do not provide, at any time, any express or implied warranty of any kind, regarding any matter pertaining to this report, including without limitation the implied warranties of merchantability, fitness for a particular purpose, and non-infringement. The recipients of this report should rely on their own investigations. This report is intended for distribution to institutional investors. Recipients who are not institutional investors should seek advice of their independent financial advisor prior to taking any investment decision based on this report or for any necessary explanation of its contents. Most and it s associates may have managed or co-managed public offering of securities, may have received compensation for investment banking or merchant banking or brokerage services, may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. Most and it s associates have not received any compensation or other benefits from the subject company or third party in connection with the research report. Subject Company may have been a client of Most or its associates during twelve months preceding the date of distribution of the research report MOSt and/or its affiliates and/or employees may have interests/positions, financial or otherwise of over 1 % at the end of the month immediately preceding the date of publication of the research in the securities mentioned in this report. To enhance transparency, MOSt has incorporated a Disclosure of Interest Statement in this document. This should, however, not be treated as endorsement of the views expressed in the report. Motilal Oswal Securities Limited is registered as a Research Analyst under SEBI (Research Analyst) Regulations, 2014. SEBI Reg. No. INH000000412 There are no material disciplinary action that been taken by any regulatory authority impacting equity research analysis activities Analyst Certification The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report. The research analysts, strategists, or research associates principally responsible for preparation of MOSt research receive compensation based upon various factors, including quality of research, investor client feedback, stock picking, competitive factors and firm revenues Disclosure of Interest Statement DR REDDY S Analyst ownership of the stock No Served as an officer, director or employee No A graph of daily closing prices of securities is available at www.nseindia.com and http://economictimes.indiatimes.com/markets/stocks/stock-quotes Regional Disclosures (outside India) This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOSt & its group companies to registration or licensing requirements within such jurisdictions. For U.S. Motilal Oswal Securities Limited (MOSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the"1934 act") and under applicable state laws in the United States. In addition MOSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement. The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account. For Hong Kong: This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) SFO. As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Kong Kong. This report is intended for distribution only to Professional Investors as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors. Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong. For Singapore Motilal Oswal Capital Markets Singapore Pte Limited is acting as an exempt financial advisor under section 23(1)(f) of the Financial Advisers Act(FAA) read with regulation 17(1)(d) of the Financial Advisors Regulations and is a subsidiary of Motilal Oswal Securities Limited in India. This research is distributed in Singapore by Motilal Oswal Capital Markets Singapore Pte Limited and it is only directed in Singapore to accredited investors, as defined in the Financial Advisers Regulations and the Securities and Futures Act (Chapter 289), as amended from time to time. In respect of any matter arising from or in connection with the research you could contact the following representatives of Motilal Oswal Capital Markets Singapore Pte Limited: Kadambari Balachandran Email : kadambari.balachandran@motilaloswal.com Contact : (+65) 68189233 / 65249115 Office Address : 21 (Suite 31),16 Collyer Quay,Singapore 04931 Motilal Oswal Securities Ltd Motilal Oswal Tower, Level 9, Sayani Road, Prabhadevi, Mumbai 400 025 29 October 2015 14 Phone: +91 22 3982 5500 E-mail: reports@motilaloswal.com